Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:25:23.780Z.
Calculation as of: 2026-10-06T13:25:23.780Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9f7ef7d03019e78f4201474ef0c74f9c2a497de6c29d743f28e52983e243880
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-04-10.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$3.15B
EBITDA Yield
1.15%
TTM Avg
0.54%
3Y Avg
0.54%
5Y Avg
0.54%
Market Cap
$3.16B
EBITDA Yield
N/A
TTM Avg
0.89%
3Y Avg
0.89%
5Y Avg
0.89%
Market Cap
$2.87B
EBITDA Yield
3.62%
TTM Avg
2.99%
3Y Avg
2.18%
5Y Avg
2.18%
Market Cap
$3.44B
EBITDA Yield
3.14%
TTM Avg
4.14%
3Y Avg
4.45%
5Y Avg
4.45%
Market Cap
$2.69B
EBITDA Yield
7.55%
TTM Avg
8.87%
3Y Avg
7.02%
5Y Avg
6.94%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.09B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 1.15% | 0.54% | 0.54% | 0.54% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | N/A | 0.89% | 0.89% | 0.89% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 3.62% | 2.99% | 2.18% | 2.18% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 1.25% | 1.25% | 1.25% | 1.25% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 3.14% | 4.14% | 4.45% | 4.45% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 7.55% | 8.87% | 7.02% | 6.94% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 10.53% | 12.59% | 12.00% | 11.83% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2024-04-10 | 936.56% |
| 2024-04-09 | 212.29% |
| 2024-04-08 | 197.73% |
| 2024-04-05 | 260.20% |
| 2024-04-04 | 272.50% |
| 2024-04-03 | 248.96% |
| 2024-04-02 | 260.20% |
| 2024-04-01 | 185.03% |
| 2024-03-28 | 130.56% |
| 2024-03-27 | 119.71% |
| 2024-03-26 | 168.78% |
| 2024-03-25 | 185.03% |
| 2024-03-22 | 168.78% |
| 2024-03-21 | 122.25% |
| 2024-03-20 | 100.86% |
| 2024-03-19 | 108.45% |
| 2024-03-18 | 124.90% |
| 2024-03-15 | 68.50% |
| 2024-03-14 | 74.72% |
| 2024-03-13 | 55.35% |
| 2024-03-12 | 55.35% |
| 2024-03-11 | 41.13% |
| 2024-03-08 | 59.95% |
| 2024-03-07 | 3.48% |
| 2024-03-06 | 3.46% |
| 2024-03-05 | 3.50% |
| 2024-03-04 | 3.44% |
| 2024-03-01 | 3.53% |
| 2024-02-29 | 3.50% |
| 2024-02-28 | 3.36% |
| 2024-02-27 | 3.47% |
| 2024-02-26 | 3.80% |
| 2024-02-23 | 3.78% |
